Astaxanthin Supplementation Lowers Dietary Intake in Healthy Subjects

2020 ◽  
Vol 19 (1) ◽  
pp. 46-51
Author(s):  
Chuenjai Sratongfaeng ◽  
Nithipun Suksumek ◽  
Nithikoon Aksorn ◽  
Pithi Chanvorachote ◽  
Kulwara Meksawan
Keyword(s):  
Dietary Intake ◽  
Controlled Trial ◽  
Low Density Lipoprotein ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Health Indicators ◽  
Lipoprotein Cholesterol ◽  
Blood Levels ◽  
Biological Parameters ◽  
Dietary Intakes

Astaxanthin, a potent antioxidant compound, is well recognized for its beneficial effects to protect from oxidative stress and free radicals. However, the effects of long period of use of astaxanthin on biological parameters, health indicators, and energy intake are still largely unknown. A total of 33 healthy participants aged 21–54 years with body mass index in the range of 18.50−24.90 kg/m2 were enrolled in this randomized controlled trial and were assigned into astaxanthin and placebo groups. The participants in the astaxanthin group received 4 mg of astaxanthin once daily for 12 consecutive weeks. Dietary intakes, as well as blood levels of astaxanthin and biological parameters, were investigated at baseline and week 12. The significant elevation of blood astaxanthin level in the astaxanthin group was notified at week 12. Regarding basic characteristics of blood biochemical parameters, results indicated that the fasting blood glucose, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol were not significantly different between astaxanthin and placebo groups at week 12. Interestingly, the significant decrease in total energy and carbohydrate intakes of the participants in the astaxanthin group (P < 0.05) was found after 12-week supplementation, compared to the baseline. The findings support the safety of long-term supplementation and reveal potential dietary intake lowering effect of astaxanthin in healthy individuals.

scholarly journals ASSOCIATION BETWEEN BLOOD LIPID PROFILE AND BLOOD GLUCOSE LEVELS IN MEN WITH CORONARY HEART DISEASE, METABOLIC SYNDROME, AND TYPE 2 DIABETES MELLITUS

2013 ◽  
Vol 12 (5) ◽  
pp. 29-33
Author(s):  
S. A. Matveeva
Keyword(s):  
Blood Glucose ◽  
Lipid Profile ◽  
Low Density Lipoprotein ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Blood Lipid ◽  
Lipoprotein Cholesterol ◽  
Blood Lipid Profile ◽  
Glucose Levels ◽  
Blood Glucose Levels

Aim.To study the associations between blood lipid profile and blood glucose levels in men with coronary heart disease (CHD), stable effort angina (SEA), metabolic syndrome (MS), and Type 2 diabetes mellitus (DM-2).Material and methods.The study included 82 men (mean age 50,5±0,9 years) with CHD, Functional Class I–III SEA, MS, and DM-2. The following lipid profile parameters were assessed: total cholesterol (TCH), triglycerides (TG), low-density lipoprotein cholesterol (LDL–CH), very low-density lipoprotein cholesterol (VLDL–CH), high-density lipoprotein cholesterol (HDL–CH), atherogenic index (AI), and triglyceride index (TGI), together with fasting blood glucose.Results.There were positive (direct) associations between higher levels (>90th percentile) of lipid profile parameters (TCH, TG, LDL–CH, VLDL– CH, HDL–CH, AI, TGI) and blood glucose, as well as between lower levels (≤10th percentile) of lipid profile parameters (TCH, TG, LDL–CH, VLDL– CH, AI, TGI) and blood glucose. At the same time, there were negative (inverse) associations between lower lipid levels (≤10th percentile of TCH, TG, LDL–CH, VLDL–CH, HDL–CH, AI, TGI) and higher glucose levels (>90th percentile), as well as between higher lipid levels (>90th percentile of TCH, TG, LDL–CH, VLDL–CH, HDL–CH, AI, TGI) and lower glucose levels (≤10th percentile).Conclusion.Dyslipidemia and hyperglycemia demonstrate synergetic proatherogenic effects in patients with CHD, SEA, MS, and DM-2, as suggested by significant heterogeneous (direct and inverse) associations between lipid profile parameters and fasting blood glucose. The results obtained provide an opportunity for the assessment of risk levels, prognosis, and need for pharmacological prevention and treatment in patients with combined cardiovascular pathology. 

scholarly journals ASSOCIATION OF SUBCLINICAL HYPOTHYROIDISM IN METABOLIC SYNDROME PATIENTSASSOCIATION OF SUBCLINICAL HYPOTHYROIDISM IN METABOLIC SYNDROME PATIENTS

2018 ◽  
Vol 11 (9) ◽  
pp. 188
Author(s):  
Jennifer S Suhashini ◽  
Savitha G
Keyword(s):  
Metabolic Syndrome ◽  
Subclinical Hypothyroidism ◽  
Low Density Lipoprotein ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Significant Difference ◽  
Tsh Levels

Objectives: Subclinical hypothyroidism (SCH) is also the major risk for cardiovascular disease like metabolic syndrome (MetS). Hence, the aim of this study is to assess the association of SCH in MetS patients.Materials and Methods: Ninety patients reporting to Saveetha Dental College and Hospitals were enrolled in the study which includes 40 patients with MetS and 40 healthy individuals. 5 ml of venous blood was collected and centrifuged. Then, it is analyzed for fasting blood sugar, serum triglycerides, high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), and very low-density lipoprotein (VLDL) using the standard kit method. Then, Free T3, Free T4, and thyroid-stimulating hormone (TSH) were estimated by ELISA method. The data obtained were subjected to statistical analysis using the SPSS software.Results: SCH is 20% in cases when compared to 4.4% in controls, which was significant, p=0.024. The biochemical parameters were compared between the study population fasting blood glucose, triglycerides, total cholesterol, low-density lipoprotein cholesterol, and VLDL cholesterol was statistically significant, with p<0.001. TSH levels showed significant difference between two groups with the p=0.002.Conclusion: MetS patients should be screened for the SCH as an important risk factor in evaluation protocol. Mere correction of TSH levels can reverse the associated morbidity in these patients rather than leaving them untreated pushing them to a state of overt hypothyroidism with its attendant complications.

Hypoglycemic Effect of Momordica charantia L. Var. Abbreviata Ser. Protein Hydrolysate Prepared with Alcalase

2012 ◽  
Vol 195-196 ◽  
pp. 324-329
Author(s):  
Xiao Qing Yuan ◽  
Chao Yuan ◽  
Hong Mei Liu
Keyword(s):  
Protein Hydrolysate ◽  
Low Density Lipoprotein ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Momordica Charantia ◽  
Lipoprotein Cholesterol ◽  
Hypoglycemic Effect ◽  
Degree Of Hydrolysis ◽  
Diabetic Mice ◽  
Long Term Study

Momordica charantia L. Var. abbreviata Ser. protein hydrolysates (MCPH) were prepared by enzymatic hydrolysis using Alcalase 2.4L. The acute hypoglycemic effect of MCPH at different degree of hydrolysis (DH) was investigated in alloxan-induced diabetic mice. The result showed the MCPH at 11% DH had the highest hypoglycemic effect. In the long-term study, repeated oral administration of MCPH at 11% DH for 28 days significantly reduced the fasting blood glucose (FBG) level, serum total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-c) levels in diabetic mice. At the same time, MCPH markedly increased body weight, serum high density lipoprotein cholesterol (HDL-c) after 28 days of treatment.

scholarly journals Randomized Control Trial Study On The Effect Of Wet Cupping On Lipid Profile

2020 ◽  
Vol 16 (2) ◽  
Author(s):  
Suhaily MH ◽  
Ismail AA ◽  
Najib MY
Keyword(s):  
Lipid Profile ◽  
Serum Lipid ◽  
Controlled Trial ◽  
Low Density Lipoprotein ◽  
Venous Blood ◽  
Intervention Group ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Control Group ◽  
The Third

Introduction: Dyslipidaemia is one of the risk factors contributing to the pathogenesis of cardiovascular   diseases (CVDs). This study was conducted to investigate the effect of wet cupping on lipid profile. Methods: This randomized controlled trial was conducted in 2012 at the School of Medical Sciences, Universiti Sains Malaysia, Malaysia. Sixty-two healthy volunteers ranging from 30 to 60 years old were randomized into control and intervention groups. Subjects in the intervention group were assigned to two sessions of wet cupping at the beginning of the study and at the third month; individuals in the control group did not undergo any cupping procedure. Venous blood sample was collected for serum lipid profile: Total Cholesterol (TC), High Density Lipoprotein Cholesterol (HDL-C), Low Density Lipoprotein Cholesterol (LDL-C), and triglycerides; measured at baseline, first, third and fourth month. Results: Subjects in the cupping group had significant improvements from baseline to third and fourth month for TC (MD=-0.56, P=0.004), HDL-C (MD=-0.22, P<0.001) and LDL-C (MD=0.58, P=0.001). There was also a significant reduction from baseline to one month for triglycerides (MD=0.38, P<0.001). Subjects in the cupping group had significantly better values in HDL-C and LDL-C as compared with the control group at the third and fourth month. Significantly lower levels of TC and triglycerides in the cupping group of the fourth month. In the control group, there were no significant changes in any serum lipid profiles. Conclusion: After two sessions of wet cupping, TC, HDL-C, LDL-C and triglycerides were significantly improved by 8.2%, 13.7%, 16.4% and 20.8% respectively.

scholarly journals Serum ferritin level as an early indicator of metabolic dysregulation in young obese adults — a cross-sectional study

2018 ◽  
Vol 96 (12) ◽  
pp. 1255-1260
Author(s):  
Harshitha Hitha ◽  
Damodara Gowda ◽  
Amrit Mirajkar
Keyword(s):  
Serum Ferritin ◽  
Serum Ferritin Level ◽  
Ferritin Level ◽  
Low Density Lipoprotein ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Cross Sectional Study ◽  
Lipoprotein Cholesterol ◽  
Cross Sectional ◽  
Metabolic Dysregulation

The aim of this study was to investigate the relationship between serum ferritin level and antioxidative status and metabolic dysregulation in young adult obese population. This cross-sectional study included 300 subjects of either sex, grouped as obese and non-obese subjects. The body mass index, total iron binding capacity, fasting blood glucose, superoxide dismutase activity, and levels of serum ferritin, iron, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglyceride, glutathione, and vitamin C were estimated. Analysis showed a significant alteration in all the parameters in obese adults. The correlation of ferritin level and body mass index showed a positive correlation (r = −0.81, p < 0.001, respectively) with levels of fasting blood glucose, superoxide dismutase, total cholesterol, low-density lipoprotein cholesterol, and triglyceride in obese individuals, whereas an insignificant correlation with vitamin C and glutathione level was observed in obese individuals. The significant positive correlation of ferritin level with the metabolic parameters and some antioxidative parameters in obese individuals signifies the development of metabolic disorders. Therefore, estimation of serum ferritin level will be an important early indicator for the risk of developing metabolic disorders in young adults.

scholarly journals Baseline low-density lipoprotein cholesterol predicts the benefit of adding ezetimibe on statin in statin-naïve acute coronary syndrome

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jihaeng Im ◽  
Erisa Kawada-Watanabe ◽  
Junichi Yamaguchi ◽  
Hiroyuki Arashi ◽  
Hisao Otsuki ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Primary Endpoint ◽  
Controlled Trial ◽  
Coronary Revascularization ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Coronary Syndrome

AbstractWe aimed to evaluate the effect of baseline low-density lipoprotein cholesterol (LDL-C) on the outcomes of patients with the acute coronary syndrome (ACS) receiving pitavastatin monotherapy or the combination of pitavastatin + ezetimibe. In the HIJ-PROPER study, 1734 ACS patients with dyslipidemia were randomly assigned to receive pitavastatin or pitavastatin + ezetimibe therapy. Statin-naïve participants (n = 1429) were divided into two groups based on the median LDL-C level (131 mg/dL) at enrollment. The primary endpoint was a composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, unstable angina, and ischemia-driven coronary revascularization. The median follow-up was 3.2 years. In the < 131 mg/dL group (n = 686), LDL-C changes were − 34.0% and − 49.8% in the pitavastatin monotherapy and pitavastatin + ezetimibe-treated groups (P < 0.0001), respectively; in the ≥ 131 mg/dL group (n = 743), LDL-C changes were − 42.9% and − 56.4% (P < 0.0001, respectively. Kaplan–Meier analyses revealed that the primary endpoint was not significantly different between the treatment groups for the < 131 mg/dL group, however, it was significantly lower in patients treated with pitavastatin + ezetimibe in the ≥ 131 mg/dL group (Hazard ratio = 0.72, 95% confidence interval = 0.56–0.91, P = 0.007, P value for interaction = 0.012). Statin-naïve ACS patients with baseline LDL-C < 131 mg/dL did not clinically benefit from pitavastatin + ezetimibe, while patients with baseline LDL-C ≥ 131 mg/dL treated with pitavastatin + ezetimibe showed better clinical results than those treated with pitavastatin monotherapy.Clinical Trial Registration: Original HIJ PROPER study; URL: http://www.umin.ac.jp/ctr. Unique Identifier; UMIN000002742, registered as an International Standard Randomized Controlled Trial.

Sign in / Sign up

Export Citation Format

Share Document